Gentian Violet Treatment for Hidradenitis Suppurativa

Status Not yet recruiting

Clinical Trial Summary

This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey responses and quantitative changes in skin appearance.

Clinical Trial Description

Hidradenitis suppurativa (HS) is a chronic disease of the folliculopilosebaceous unit, often found in intertriginous areas of the body. The pain and impairment of HS leads patients to report a decreased quality of life, even in comparison to other debilitating cutaneous disease states. Pharmalogic management of HS can vary from topical antibiotics or intralesional corticosteroids for mild cases to immunosuppressants and biologic agents in refractory cases. Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration. It is our hypothesis that gentian violet will help minimize skin trauma in sites of active HS to promote improved wound healing and quality of life. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04388163
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact	Irma M Richardson, MHA
Phone	336-716-2903
Email	irichard@wakehealth.edu
Status	Not yet recruiting
Phase	Phase 2
Start date	July 2024
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02904902` - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa	Phase 3
Completed	`NCT03628924` - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)	Phase 2
Not yet recruiting	`NCT05531747` - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa	N/A
Recruiting	`NCT06028230` - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Completed	`NCT03275870` - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa	Phase 1/Phase 2
Completed	`NCT03248531` - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.	Phase 2
Withdrawn	`NCT04100083` - Spironolactone for Hidradenitis Suppurativa	Phase 4
Completed	`NCT00329823` - Etanercept in Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT05710393` - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed	`NCT04019041` - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa	Phase 2
Completed	`NCT05286567` - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.	Phase 1
Withdrawn	`NCT03929835` - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa	Phase 2
Terminated	`NCT04325607` - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa	N/A
Terminated	`NCT03238469` - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa	N/A
Completed	`NCT04449354` - HidraWear AX HS Study	N/A
Recruiting	`NCT06123429` - Mindfulness in Hidradenitis Suppurativa	N/A
Recruiting	`NCT05934825` - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa	Phase 1/Phase 2
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT06046729` - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 2
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2